Erlotinib response in an NSCLC patient with a novel compound G719D+L861R mutation in EGFR.
作者信息
Berge Eamon M, Aisner Dara L, Doebele Robert C
机构信息
Departments of Medicine, Division of Medical Oncology, University of Colorado School of Medicine, Aurora, CO 80045, USA.
出版信息
J Thorac Oncol. 2013 Sep;8(9):e83-4. doi: 10.1097/JTO.0b013e31829ceb8d.
Abstract
摘要
相似文献
1
Erlotinib response in an NSCLC patient with a novel compound G719D+L861R mutation in EGFR.一名非小细胞肺癌患者携带表皮生长因子受体（EGFR）新型复合突变G719D+L861R对厄洛替尼的反应
J Thorac Oncol. 2013 Sep;8(9):e83-4. doi: 10.1097/JTO.0b013e31829ceb8d.
2
EGFR delE709_T710insD: a rare but potentially EGFR inhibitor responsive mutation in non-small-cell lung cancer.表皮生长因子受体（EGFR）E709_T710缺失并插入D：非小细胞肺癌中一种罕见但可能对EGFR抑制剂敏感的突变
J Thorac Oncol. 2012 Oct;7(10):e19-20. doi: 10.1097/JTO.0b013e3182635ab4.
3
Personalized medicine and inhibition of EGFR signaling in lung cancer.肺癌中的个性化医疗与表皮生长因子受体信号传导抑制
N Engl J Med. 2009 Sep 3;361(10):1018-20. doi: 10.1056/NEJMe0905763. Epub 2009 Aug 19.
4
Two generations of light/never-smokers with advanced adenocarcinoma of the lung with durable responses to erlotinib.两代患有晚期肺腺癌且对厄洛替尼有持久反应的从不吸烟者。
J Thorac Oncol. 2012 Jul;7(7):1200-1. doi: 10.1097/JTO.0b013e318250ed89.
5
Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.表皮生长因子受体（EGFR）突变的肺癌对吉非替尼获得性耐药并携带L747S或T790M继发性突变时，对厄洛替尼的不同反应。
J Clin Oncol. 2008 Mar 1;26(7):1182-4; author reply 1184-6. doi: 10.1200/JCO.2007.14.9039.
6
Clinical outcomes and prognostic factors associated with the response to erlotinib in non-small-cell lung cancer patients with unknown EGFR mutational status.表皮生长因子受体（EGFR）突变状态未知的非小细胞肺癌患者中，与厄洛替尼反应相关的临床结局和预后因素
Asian Pac J Cancer Prev. 2013;14(5):3255-61. doi: 10.7314/apjcp.2013.14.5.3255.
7
Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib.表皮生长因子受体（EGFR）S768I突变型肺腺癌对厄洛替尼敏感的临床及体内证据。
J Thorac Oncol. 2014 Oct;9(10):e73-4. doi: 10.1097/JTO.0000000000000221.
8
Serum concentrations of Erlotinib at a dose of 25 mg daily.每日剂量为25毫克时厄洛替尼的血清浓度。
J Thorac Oncol. 2010 Aug;5(8):1311-2. doi: 10.1097/JTO.0b013e3181edf55c.
9
The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.表皮生长因子受体突变的晚期非小细胞肺癌中初始吉非替尼或厄洛替尼与化疗对中枢神经系统进展的影响。
Clin Cancer Res. 2012 Aug 15;18(16):4406-14. doi: 10.1158/1078-0432.CCR-12-0357. Epub 2012 Jun 25.
10
Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?非小细胞肺癌分子靶向维持治疗的时机到了吗？
Lancet Oncol. 2010 Jun;11(6):500-1. doi: 10.1016/S1470-2045(10)70120-0. Epub 2010 May 20.
引用本文的文献
1
Case report: Favorable efficacy of combined afatinib and anlotinib treatment in a lung adenocarcinoma patient harboring uncommon L858M/L861R mutations.病例报告：阿法替尼与安罗替尼联合治疗一名携带罕见L858M/L861R突变的肺腺癌患者的疗效良好。
Front Pharmacol. 2024 Nov 29;15:1437086. doi: 10.3389/fphar.2024.1437086. eCollection 2024.
2
Activity of afatinib in patients with NSCLC harboring novel uncommon mutations with or without co-mutations: a case report.阿法替尼在伴有或不伴有共突变的携带新型罕见突变的非小细胞肺癌患者中的活性：一例报告
Front Oncol. 2024 May 6;14:1347742. doi: 10.3389/fonc.2024.1347742. eCollection 2024.
3
Pathogenic mutation hotspots in protein kinase domain structure.蛋白激酶结构域中的致病变异热点。
Protein Sci. 2023 Sep;32(9):e4750. doi: 10.1002/pro.4750.
4
Compound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma.复合表皮生长因子受体（EGFR）突变常与可靶向治疗基因的共突变同时出现，并与肺腺癌的不良临床预后相关。
Cancer Biol Ther. 2016;17(3):237-45. doi: 10.1080/15384047.2016.1139235. Epub 2016 Jan 19.
5
The study of homology between tumor progression genes and members of retroviridae as a tool to predict target-directed therapy failure.研究肿瘤进展基因与逆转录病毒科成员之间的同源性，以此作为预测靶向治疗失败的一种工具。
Front Pharmacol. 2015 May 1;6:92. doi: 10.3389/fphar.2015.00092. eCollection 2015.
6
EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer.表皮生长因子受体（EGFR）突变作为非小细胞肺癌的预后和预测标志物
Drug Des Devel Ther. 2014 Sep 26;8:1595-611. doi: 10.2147/DDDT.S69690. eCollection 2014.
7
Drug resistance missense mutations in cancer are subject to evolutionary constraints.癌症中的耐药性错义突变受到进化限制。
PLoS One. 2013 Dec 20;8(12):e82059. doi: 10.1371/journal.pone.0082059. eCollection 2013.
本文引用的文献
1
Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.复合 EGFR 突变与 EGFR 酪氨酸激酶抑制剂的反应。
J Thorac Oncol. 2013 Jan;8(1):45-51. doi: 10.1097/JTO.0b013e3182781e35.
2
A novel EGFR mutation in exon 18 with high sensitivity to EGFR TKI treatment with reduced dose.外显子18中一种对低剂量EGFR TKI治疗具有高敏感性的新型EGFR突变。
J Thorac Oncol. 2012 Nov;7(11):e32. doi: 10.1097/JTO.0b013e31826d8f66.
3
Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.酪氨酸激酶抑制剂对非小细胞肺癌中未知临床意义的“罕见”表皮生长因子受体突变的疗效。
Clin Cancer Res. 2011 Jun 1;17(11):3812-21. doi: 10.1158/1078-0432.CCR-10-3408. Epub 2011 Apr 29.
4
Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer.表皮生长因子受体与肿瘤发生的关系：EGFR 基因与癌症。
FEBS J. 2010 Jan;277(2):301-8. doi: 10.1111/j.1742-4658.2009.07448.x. Epub 2009 Nov 18.
5
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.表皮生长因子受体中的激活突变是非小细胞肺癌对吉非替尼产生反应的基础。
N Engl J Med. 2004 May 20;350(21):2129-39. doi: 10.1056/NEJMoa040938. Epub 2004 Apr 29.
Zotero 插件